Poxel
Founded Year
2009Stage
IPO | IPOTotal Raised
$51.12MDate of IPO
2/6/2015Market Cap
0.03BStock Price
0.75About Poxel
Poxel is a biopharmaceutical company developing first-in-class drugs, with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof-of-concept before seeking pharmaceutical industry partners. Poxel was spun out from Merck Serono. It operates independently as a lean organization with strong in-house drug development expertise. Poxel's product pipeline consists of several first-in-class Type 2 diabetes products, including Imeglimin in Phase II development. Recently, Imeglimin has also shown significant clinical benefits in Type 2 diabetes, when added to sitagliptin. The Phase II study achieved the primary and secondary endpoints. Previously, Imeglimin has shown incremental efficacy as an add-on therapy to metformin, in patients inadequately controlled by monotherapy. In addition, a direct activator of AMPK is in preclinical development for the treatment of Type 2 diabetes.
Missing: Poxel's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Poxel's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Poxel
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Poxel is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Diabetes
1,904 items
Poxel Patents
Poxel has filed 28 patents.
The 3 most popular patent topics include:
- Rare diseases
- Autosomal recessive disorders
- Transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/7/2021 | 5/3/2022 | Transcription factors, Human proteins, Intracellular receptors, Rare diseases, Fluoroarenes | Grant |
Application Date | 5/7/2021 |
|---|---|
Grant Date | 5/3/2022 |
Title | |
Related Topics | Transcription factors, Human proteins, Intracellular receptors, Rare diseases, Fluoroarenes |
Status | Grant |
Latest Poxel News
Mar 15, 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023. The Company will present the positive results from the P
Poxel Frequently Asked Questions (FAQ)
When was Poxel founded?
Poxel was founded in 2009.
Where is Poxel's headquarters?
Poxel's headquarters is located at 200 avenue Jean Jaurès, Lyon.
What is Poxel's latest funding round?
Poxel's latest funding round is IPO.
How much did Poxel raise?
Poxel raised a total of $51.12M.
Who are the investors of Poxel?
Investors of Poxel include Kreos Capital, Bpifrance, Omnes Capital, Andera Partners, CDC Entreprises and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.